MetaCap

Avalo Therapeutics (AVTX) vs Phathom Pharmaceuticals (PHAT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avalo Therapeutics (AVTX) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 62.1% versus a loss of 68.9%. Over five years, PHAT leads with a -76.5% price change compared with -99.9% for AVTX. Avalo Therapeutics is the larger company by market cap ($390.9 million vs $378.8 million), about 1.0 times the size, while Phathom Pharmaceuticals is growing revenue faster (+216.9% vs -86.6%).

Phathom Pharmaceuticals converts more of its revenue into profit, with a net margin of -126.3% versus -132642.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVTX-62.09%PHAT-68.93%
+33%-20%-74%
Nov 21, 20251 yearNov 20, 2026
AVTX-99.89%PHAT-76.79%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVTX versus PHAT key metrics
MetricAVTXPHAT
Share price$6.76$4.66
Market cap$390.88M$378.82M
1-day change+0.15%-8.27%
YTD return-62.78%-71.91%
1-year return-62.09%-68.93%
5-year return-99.89%-76.46%
Forward P/E—5.18
EPS (TTM)$-2.26$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$59.00K$175.11M
Revenue growth (YoY)-86.62%+216.93%
Net income (latest FY)$-78.26M$-221.25M
Gross margin—87.09%
Operating margin-123601.69%-91.36%
Net margin-132642.37%-126.35%
52-week high$24.27$18.31
52-week low$6.53$4.62
Distance from 52-week high-72.15%-74.55%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+414.79%+321.67%
Average volume1.80M1.45M
Shares outstanding57.82M81.29M
Employees33371
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Phathom Pharmaceuticals is more profitable, keeping -126.3 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
  • Phathom Pharmaceuticals grew revenue faster in its latest fiscal year (+216.93% vs -86.62%).

About Avalo Therapeutics

AVTX stock →

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Phathom Pharmaceuticals

PHAT stock →

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.

Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees

AVTX vs PHAT FAQ

Which is bigger, Avalo Therapeutics or Phathom Pharmaceuticals?

Avalo Therapeutics (AVTX) is larger, with a market capitalization of $390.88M compared with $378.82M for Phathom Pharmaceuticals (PHAT).

Which stock has performed better over the past year, AVTX or PHAT?

AVTX returned -62.09% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.

Are Avalo Therapeutics and Phathom Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons